New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 6, 2017 – Alkermes announced the FDA approval of two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension, for the treatment of schizophrenia.
Download PDF
Return to publications
